Singapore Clinical Chemistry and Immunodiagnostic Analyzers and Reagents 2024-2029 - High-Growth Opportunities for Suppliers, Competitive Analysis and Growth Strategies, Latest Technologies and Instrumentation Pipeline

This report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the clinical chemistry and immunodiagnostic markets during the next five years. The report provides specimen, test volume and Sales Segment forecasts; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.

Rationale

The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.

Individual Tests Analyzed in the Report

Clinical Chemistry

Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin (Direct), Bilirubin (Total), BNP, BUN (Blood Urea Nitrogen), Calcium, Carbon Dioxide/Bicarbonate, Cardio CRP, Chloride, Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Cystatin C, Ferritin, Fructosamine, GGT, Glucose, HDL Cholesterol, Homocysteine, hs-CRP, Insulin, Iron, Iron (Total Binding Capacity), Iron (Unsaturated Binding Capacity), LDH, LDL Cholesterol, LDL Cholesterol Direct, Lipase, Lipoprotein a, Magnesium, Microalbumin, NT-proBNP, Phosphorus, Potassium, Sodium, ST2, Total Protein, Triglycerides, Troponin, Uric Acid

Therapeutic Drug Monitoring (TDM)

Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin

Endocrine Function

Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH, Prolactin, T3, T3 Free, T3 Uptake, T4, T4 Free, TBG, Testosterone, Thyroglobulin Ab, TPO Ab, TSH

Tumor Markers and Special Chemistry

AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid), Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood, PAP, PSA, Thyroglobulin, Vitamin B-12

Immunoproteins

C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM, Immunofixation, Prealbumin, Protein Electrophoresis

Drugs of Abuse

Amphetamines, Antidepressants, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine, LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP), Propoxyphene, Tricyclic Antidepressants

Current and Emerging Products

• Analysis of current and emerging clinical chemistry and immunodiagnostic tests.
• Review of current instrumentation technologies, and feature comparison of high-, medium-, and low-volume/POC analyzers.

Technology Assessment

• Assessment of current and emerging technologies, and their potential market applications.
• Comprehensive lists of companies developing or marketing new technologies and products by test.

Strategic Recommendations

• New product development opportunities with significant market appeal.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their Sales Segment, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.